Latest announcements

  • Notice of Board Meeting for Audited Financial Results and Dividend, if any
    11.05.2022
    Read More
  • Disclosure of material event – Update on Assignment of Trademark for Azmarda® indicated for heart failure patients with reduced ejection fraction (HfrEF) from Novartis AG, Switzerland for India
    13.04.2022
    Read More
  • Assignment of Trademark for Azmarda® from Novartis AG, Switzerland for India
    01.04.2022
    Read More
  • Disclosure of material event – Resignation of Director
    14.03.2022
    Read More
  • Intimation of record date for Interim Dividend
    14.02.2022
    Read More
  • Declaration of Interim Dividend for FY 2021-22
    14.02.2022
    Read More
  • Q3 FY22 Press Release
    14.02.2022
    Read More
  • Q3 FY22 Investor Presentation
    14.02.2022
    Read More
  • Q3 FY22 Results Sheet
    14.02.2022
    Read More
  • Schedule of Investors /Analysts’ call with Management on 15.02.2022 and Registration Log-in details.
    08.02.2022
    Read More
  • Investor presentation in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited – 27.01.2022
    27.01.2022
    Read More
  • Disclosure of material event – Resignation of Director
    27.01.2022
    Read More
  • Press Release in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited
    27.01.2022
    Read More
  • Disclosure of material event – Acquisition of Brands and Related Assets from Sanzyme Private Limited
    27.01.2022
    Read More
  • Schedule of Investors / Analysts’ call with Management on 27.01.2022 and Registration Log-in details for the same
    26.01.2022
    Read More
  • Press Release regarding the launch of Molupiravir for the Indian market
    29.12.2021
    Read More
  • Q2 Results 2021-CNBC TV18
    15.11.2021
    Read More
  • Q2 FY22 Press Release
    11.11.2021
    Read More
  • Q2 FY22 Investor Presentation
    11.11.2021
    Read More
  • Q2 FY22 Results Sheet
    11.11.2021
    Read More
  • Grant of options under ESOS Scheme
    01.10.2021
    Read More
  • Change in Key Managerial Personnel
    01.10.2021
    Read More
  • Disclosure of Material events/ information – Submission of application to Stock Exchanges for reclassification
    17.09.2021
    Read More
  • AGM Recording
    15.09.2021
    Read More
  • Disclosure of material event/information – Re-classification of status from promoter to public of certain promoters/promoter group members
    10.09.2021
    Read More
  • Disclosure of material event/information – Appointment of Statutory Auditor
    10.09.2021
    Read More
  • Disclosure of material event/information – Proceedings of the Annual General Meeting
    10.09.2021
    Read More
  • Result of voting at Annual General Meeting
    10.09.2021
    Read More
  • Disclosure of material event/information – Resignation of Chief Financial Officer
    07.09.2021
    Read More
  • Presentation made to Investors – 12.08.2021
    12.08.2021
    Read More
  • Unaudited Financial Results 31.12.2020
    19.07.2021
    Read More
  • Intimation of Record Date
    19.07.2021
    Read More
  • Press Release for Unaudited Financial Results – 31.12.2020
    19.07.2021
    Read More
  • Presentation made to Investors – 10.02.2021
    19.07.2021
    Read More
  • Schedule of meeting with institutional investors
    19.07.2021
    Read More
  • Presentation made to Investors – 02.03.2021
    19.07.2021
    Read More
  • Outcome of Board meeting
    19.07.2021
    Read More
  • Institution of new Employee Stock Option Scheme
    19.07.2021
    Read More
  • Launch of new dedicated division “RENOVA” to enter Nephrology segment in India
    19.07.2021
    Read More
  • Disclosure of receipt of requests from the promoters/ promoter group members seeking re-classification of status as public
    19.07.2021
    Read More
  • Notice of Board Meeting
    19.07.2021
    Read More
  • Recommendation of final dividend
    19.07.2021
    Read More
  • Schedule of Investors/ Analysts’ call with management on 15.06.2021 and Registration/Log-in details for the same
    19.07.2021
    Read More
  • Audited Financial Results 31.03.2021
    19.07.2021
    Read More
  • Press Release for Audited Financial Results – 31.03.2021
    19.07.2021
    Read More
  • Q4 FY21 Earnings Call Transcript
    19.07.2021
    Read More
  • Instructions
    19.07.2021
    Read More
  • Postal Ballot Form
    19.07.2021
    Read More
  • Disclosure of material event/information – 02.07.2021
    19.07.2021
    Read More
  • Newspaper advertisement for Postal Ballot
    19.07.2021
    Read More
  • FY 2019 – 2020
    15.07.2021
    Read More
  • FY 2019 – 2020
    15.07.2021
    Read More
  • Q1 FY22 Earnings Call Audio
    30.06.2021
    Read More
  • Postal Ballot Notice – 25.06.2021
    25.06.2021
    Read More
  • Recommendation of Final Dividend for FY 2020-21
    14.06.2021
    Read More
  • Views of Board of Directors on the Reclassification Request
    08.06.2021
    Read More
  • Newspaper cutting of extract of Consolidated Financial Results 31.03.2021
    31.03.2021
    Read More
  • Registration/ Log-in details for virtual call with management on 02.03.2021
    02.03.2021
    Read More
  • Declaration of Interim Dividend
    10.02.2021
    Read More
  • Board to consider and declare interim dividend for FY 2020-21
    05.02.2021
    Read More